Heart failure

  title={Heart failure},
  author={John J. V. McMurray and Marc A. Pfeffer},
  journal={The Lancet},

Worsening Heart Failure and Atrial Flutter in a Patient Secondary to Cardiac Resynchronization Therapy Dyssynchrony: A Case Report

A case of 59-year-old patient who presented with worsening shortness of breath (SOB) and progressive exertional dyspnea for the past few weeks accompanied by pink, frothy sputum, occasional urinary incontinence and urge is presented.

Management of atrial fibrillation in patients with heart failure.

In conclusion, AF is associated with increased mortality in CHF patients, however, it is not clear whether there is a causal relationship.

Cardio-renal and cardio-hepatic interactions predict cardiovascular events in elderly patients with heart failure

Cardio-renal and cardio-hepatic interactions predicted CV events in aged HF patients, and patients with high MELD-XI showed a worse prognosis than those with lower scores.

Predictors of long-term adverse outcomes in elderly patients over 80 years hospitalized with heart failure. - A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD)-.

Among patients hospitalized with HF, elderly patients had a worse prognosis than younger patients, and lower eGFR, lower BMI, male sex, sustained VT/VF, and diuretic use were independent predictors for all-cause death in these patients with higher risk.

The role of diabetes in cardiomyopathies of different etiologies—Characteristics and 1-year follow-up results of the EVITA-HF registry

The influence of diabetes on the mortality rate is only significant in Patients with DCM not in patients with CAD, and the underlying mechanisms of this effect should be studied in greater detail to improve patient care and outcome.

Myocardial α2-Adrenoceptors as Therapeutic Targets to Prevent Cardiac Hypertrophy and Heart Failure

This review analyzes cardiomyocyte α2-AR signaling, which counteracts intracellular Ca2+ overload and angiotensin-induced cardiac hypertrophy, and suppose that in heart failure-linked desensitization of these receptors, cardiac-specific cell- or gene-based therapies aimed at repairing or amplifyingα2- AR signaling could offer prospects for a prevention of cardiachypertrophy and heart failure.